Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974140 · ClinicalTrials.gov registry record · NA
Cataract Refractive Suite Study
A NA study, sponsored by Alcon, a Novartis Company.
- Terminated
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT02974140: Clinical Trial NA study, sponsored by Alcon, a Novartis Company.
NCT02974140 is a NA study that was terminated before completion, run by Alcon, a Novartis Company. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02974140, a NA study, was terminated before completion, sponsored by Alcon, a Novartis Company.
- TERMINATED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the refractive predictability (prediction error) between the Cataract Refractive Suite (CRS) and standard manual technique at one month post-operative
Primary Outcome
Manifest refraction spherical equivalent (MRSE) was calculated as follows: sphere + 1/2 cylinder. The sphere and cylinder values were from the manifest refraction assessment. Manifest refraction was assessed at 4 meters under photopic lighting conditions using a phoropter. Due to early termination of the study and limited sample size, a statistical inference test was not carried out as planned.
Interventions
- DEVICE Cataract Refractive Suite (CRS)
- PROCEDURE Standard manual technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2017-07-25 |
| Phase | NA |
Why NCT02974140 stopped before completion
NCT02974140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Cataract Refractive Suite (CRS) is the first listed.
NCT02974140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02974140 about?
NCT02974140 is a clinical study titled "Cataract Refractive Suite Study". The purpose of this study is to compare the refractive predictability (prediction error) between the Cataract Refractive Suite (CRS) and standard manual technique at one month post-operative
What is the current status of trial NCT02974140?
This trial is currently terminated. It is a NA study. The enrollment target is 39 participants. The study started on 2017-03-02. Estimated completion is 2017-07-25.
What interventions are being tested in trial NCT02974140?
The interventions under investigation include: Cataract Refractive Suite (CRS) (DEVICE), Standard manual technique (PROCEDURE).
Who is sponsoring clinical trial NCT02974140?
This trial is sponsored by Alcon, a Novartis Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02974140's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI